FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986835513> ?p ?o ?g. }

• W1986835513 endingPage "619" @default.
• W1986835513 startingPage "611" @default.
• W1986835513 abstract "Previously, we have reported the successful expression of human aldehyde dehydrogenase class-1 (ALDH-1) in K562 leukemia cells using a retroviral vector and demonstrated low expression that resulted in up to threefold increase in resistance to 4-hydroperoxycyclophosphamide (4-HC), an active derivative to cyclophosphamide. The purpose of this study was to investigate whether in vitro treatment with 4-HC will allow selection of K562 cells expressing higher levels of ALDH-1, and whether these selected cells are more resistant to 4-HC. Stably transfected or transduced K562 cells with retroviral pLXSN vector containing ALDH-1 cDNA (ALDH-1 cells) were treated repeatedly with 4-HC and then allowed to grow to confluence in liquid culture. Subsequently, the resistance to 4-HC of ALDH-1 cells treated once (ALDH-1+) or twice (ALDH-1++) with 4-HC was compared to ALDH-1 cells or wild-type K562 cells (WT cells). The results show significant increase in 4-HC resistance of ALDH-1+ (2- to 16-fold, p < 0.005) over ALDH-1 or WT cells. No difference was detected between ALDH-1+ and ALDH-1++. In addition, higher ALDH-1 mRNA and enzyme activity were found in ALDH-1+ compared to ALDH-1 cells. Southern analysis of DNA extracted from the different experimental groups demonstrated an eight-fold increase in ALDH-1 cDNA in ALDH-1 + versus the ALDH-1 cells. This was confirmed by sequential FISH analysis using biotin labeled pLXSN/ALDH-1 vector. Positive signals consistently localized to the centromeric region of chromosome 9 and the long arm of chromosome 17 were demonstrated only in the ALDH-1+ cells and represented a fusion product of multiple copies of the pLXSN/ALDH-1 vector. In summary, we have demonstrated that in vitro treatment with 4-HC results in the selection of K562 cells with multiple copies of ALDH-1 gene that are clustered in two main integration sites. These cells demonstrate significantly higher resistance to 4-HC when compared to previously untreated cells. Such successful in vitro selection could have significant implications for future cancer gene therapy protocols. Transfer of drug resistance genes into hematopoietic progenitors is an important developing field in cancer gene therapy. However, the main problems remain achieving high transfer efficiency as well as high functional expression of the gene of interest. Previously, we have reported the successful expression of low levels of ALDH-1 in K562 leukemic cells with up to three-fold increase in resistance to 4-HC. In this study, we used 4-HC treatment to select for K562 cells with the highest pLXSN/ALDH-1 copy number and ALDH-1 expression. We showed that cells surviving one treatment of 4-HC (ALDH-1+) indeed have significantly higher ALDH-1 expression and enzyme activity when compared to untreated ALDH-1 or WT K562 cells. Furthermore, Southern analysis confirmed that the in vitro treatment with 4-HC resulted in the selection of cells with higher copy numbers of ALDH-1 cDNA. FISH analysis using biotin-labeled pLXSN/ALDH-1 vector showed positive signal only in the ALDH-1+ cells. Interestingly, two integration sites of pLXSN/ALDH-1 fusion product were detected. These results may have significant clinical implications, especially in the design of clinical gene therapy protocols. In the setting of autologous stem cell transplantation, the in vitro selection of hematopoietic stem cells with the highest levels of ALDH-1 may allow these cells to compete better in the repopulation of the hematopoietic system and thus allow the use of high doses of cyclophosphamide repeatedly after autologous transplantation." @default.
• W1986835513 created "2016-06-24" @default.
• W1986835513 creator A5047120666 @default.
• W1986835513 creator A5055611640 @default.
• W1986835513 creator A5069390767 @default.
• W1986835513 creator A5069756891 @default.
• W1986835513 creator A5087573996 @default.
• W1986835513 date "1998-03-20" @default.
• W1986835513 modified "2023-09-26" @default.
• W1986835513 title "<i>In Vitro</i>Selection for K562 Cells with Higher Retrovirally Mediated Copy Number of Aldehyde Dehydrogenase Class-1 and Higher Resistance to 4-Hydroperoxycyclophosphamide" @default.
• W1986835513 cites W1584828020 @default.
• W1986835513 cites W1974181247 @default.
• W1986835513 cites W2014687982 @default.
• W1986835513 cites W2031294163 @default.
• W1986835513 cites W2055531366 @default.
• W1986835513 cites W2060015200 @default.
• W1986835513 cites W2069644796 @default.
• W1986835513 cites W2092941260 @default.
• W1986835513 cites W2111486924 @default.
• W1986835513 cites W2159674215 @default.
• W1986835513 cites W2171082082 @default.
• W1986835513 cites W2193086122 @default.
• W1986835513 cites W2298126938 @default.
• W1986835513 cites W2439269229 @default.
• W1986835513 cites W4233760087 @default.
• W1986835513 cites W4245834423 @default.
• W1986835513 cites W4248229196 @default.
• W1986835513 cites W4253533771 @default.
• W1986835513 cites W70451531 @default.
• W1986835513 doi "https://doi.org/10.1089/hum.1998.9.5-611" @default.
• W1986835513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9551609" @default.
• W1986835513 hasPublicationYear "1998" @default.
• W1986835513 type Work @default.
• W1986835513 sameAs 1986835513 @default.
• W1986835513 citedByCount "32" @default.
• W1986835513 countsByYear W19868355132013 @default.
• W1986835513 countsByYear W19868355132016 @default.
• W1986835513 countsByYear W19868355132018 @default.
• W1986835513 countsByYear W19868355132022 @default.
• W1986835513 crossrefType "journal-article" @default.
• W1986835513 hasAuthorship W1986835513A5047120666 @default.
• W1986835513 hasAuthorship W1986835513A5055611640 @default.
• W1986835513 hasAuthorship W1986835513A5069390767 @default.
• W1986835513 hasAuthorship W1986835513A5069756891 @default.
• W1986835513 hasAuthorship W1986835513A5087573996 @default.
• W1986835513 hasConcept C153911025 @default.
• W1986835513 hasConcept C171122931 @default.
• W1986835513 hasConcept C181199279 @default.
• W1986835513 hasConcept C185592680 @default.
• W1986835513 hasConcept C202751555 @default.
• W1986835513 hasConcept C25747580 @default.
• W1986835513 hasConcept C55493867 @default.
• W1986835513 hasConcept C86803240 @default.
• W1986835513 hasConceptScore W1986835513C153911025 @default.
• W1986835513 hasConceptScore W1986835513C171122931 @default.
• W1986835513 hasConceptScore W1986835513C181199279 @default.
• W1986835513 hasConceptScore W1986835513C185592680 @default.
• W1986835513 hasConceptScore W1986835513C202751555 @default.
• W1986835513 hasConceptScore W1986835513C25747580 @default.
• W1986835513 hasConceptScore W1986835513C55493867 @default.
• W1986835513 hasConceptScore W1986835513C86803240 @default.
• W1986835513 hasIssue "5" @default.
• W1986835513 hasLocation W19868355131 @default.
• W1986835513 hasLocation W19868355132 @default.
• W1986835513 hasOpenAccess W1986835513 @default.
• W1986835513 hasPrimaryLocation W19868355131 @default.
• W1986835513 hasRelatedWork W2004358314 @default.
• W1986835513 hasRelatedWork W2005224022 @default.
• W1986835513 hasRelatedWork W2043747644 @default.
• W1986835513 hasRelatedWork W2143734654 @default.
• W1986835513 hasRelatedWork W2146852610 @default.
• W1986835513 hasRelatedWork W2362057675 @default.
• W1986835513 hasRelatedWork W2371554590 @default.
• W1986835513 hasRelatedWork W2796450422 @default.
• W1986835513 hasRelatedWork W3035417736 @default.
• W1986835513 hasRelatedWork W84710734 @default.
• W1986835513 hasVolume "9" @default.
• W1986835513 isParatext "false" @default.
• W1986835513 isRetracted "false" @default.
• W1986835513 magId "1986835513" @default.
• W1986835513 workType "article" @default.